drugset / Trial / NCT06943859

Ketamine for Opioid Use Disorder

NCT06943859 ↗

Phase 2 Recruiting 50 enrolled University of Maryland, Baltimore
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults entering methadone treatment for opioid use disorder. The main questions it aims to answer are: * Does ketamine reduce craving for opioids in patients with opioid use disorder? * Does ketamine reduce symptoms of opioid withdrawal such as depression, pain, and poor sleep quality? * Do patients who take the low dose ketamine stay in methadone treatment longer, and/or have better treatment outcomes than those given the very low dose? Researchers will compare two low doses of ketamine to see if ketamine works to reduce craving for opioids in adults entering methadone treatment for opioid use disorder. Participants will: * Be given a low dose or a very low dose of ketamine 4 times over a period of 2 weeks * Visit the clinic weekly and monthly for checkups and tests for 90 days post-intake

Timeline

Start
2026-02-04
Primary completion
2028-08-31
Completion
2029-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.1 mg/kg Intramuscular
Subject Ketamine Small molecule 0.75 mg/kg Intramuscular